European Union - English - EMA (European Medicines Agency)

bayer pharma ag - regorafenib - colorectal neoplasms - antineoplastic agents, protein kinase inhibitors - stivarga is indicated as monotherapy for the treatment of adult patients with:metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies - these include fluoropyrimidine-based chemotherapy, an anti-vegf therapy and an anti-egfr therapy;unresectable or metastatic gastrointestinal stromal tumors (gist) who progressed on or are intolerant to prior treatment with imatinib and sunitinib;hepatocellular carcinoma (hcc) who have been previously treated with sorafenib.

Canada - English - Health Canada

bayer inc - regorafenib - tablet - 40mg - regorafenib 40mg - antineoplastic agents

Israel - English - Ministry of Health

bayer israel ltd - regorafenib - film coated tablets - regorafenib 40 mg - regorafenib - regorafenib - stivarga is indicated as monotherapy for the treatment of adults patients:- with metastatic colorectal cancer (crc) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf therapy,and if kras wild- type, an anti-egfr therapy.- with locally advanced, unresectable or metastatic gastrointestinal stromal tumors (gist) who have been previously treated with imatinib mesylate and sunitinib malate.- hepatocellular carcinoma (hcc) who have been previously treated with sorafenib.